Cargando…
Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)
| Autores principales: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7278203/ https://www.ncbi.nlm.nih.gov/pubmed/32513251 http://dx.doi.org/10.1186/s13063-020-04408-w |
| _version_ | 1783543286637527040 |
|---|---|
| author | Yamashita, Toshinari Masuda, Norikazu Saji, Shigehira Araki, Kazuhiro Ito, Yoshinori Takano, Toshimi Takahashi, Masato Tsurutani, Junji Koizumi, Kei Kitada, Masahiro Kojima, Yasuyuki Sagara, Yasuaki Tada, Hiroshi Iwasa, Tsutomu Kadoya, Takayuki Iwatani, Tsuguo Hasegawa, Hiroki Morita, Satoshi Ohno, Shinji |
| author_facet | Yamashita, Toshinari Masuda, Norikazu Saji, Shigehira Araki, Kazuhiro Ito, Yoshinori Takano, Toshimi Takahashi, Masato Tsurutani, Junji Koizumi, Kei Kitada, Masahiro Kojima, Yasuyuki Sagara, Yasuaki Tada, Hiroshi Iwasa, Tsutomu Kadoya, Takayuki Iwatani, Tsuguo Hasegawa, Hiroki Morita, Satoshi Ohno, Shinji |
| author_sort | Yamashita, Toshinari |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7278203 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-72782032020-06-09 Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD) Yamashita, Toshinari Masuda, Norikazu Saji, Shigehira Araki, Kazuhiro Ito, Yoshinori Takano, Toshimi Takahashi, Masato Tsurutani, Junji Koizumi, Kei Kitada, Masahiro Kojima, Yasuyuki Sagara, Yasuaki Tada, Hiroshi Iwasa, Tsutomu Kadoya, Takayuki Iwatani, Tsuguo Hasegawa, Hiroki Morita, Satoshi Ohno, Shinji Trials Correction BioMed Central 2020-06-08 /pmc/articles/PMC7278203/ /pubmed/32513251 http://dx.doi.org/10.1186/s13063-020-04408-w Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| spellingShingle | Correction Yamashita, Toshinari Masuda, Norikazu Saji, Shigehira Araki, Kazuhiro Ito, Yoshinori Takano, Toshimi Takahashi, Masato Tsurutani, Junji Koizumi, Kei Kitada, Masahiro Kojima, Yasuyuki Sagara, Yasuaki Tada, Hiroshi Iwasa, Tsutomu Kadoya, Takayuki Iwatani, Tsuguo Hasegawa, Hiroki Morita, Satoshi Ohno, Shinji Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD) |
| title | Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD) |
| title_full | Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD) |
| title_fullStr | Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD) |
| title_full_unstemmed | Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD) |
| title_short | Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD) |
| title_sort | correction to: trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for her2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase iii trial in japan (jbcrg-m06/emerald) |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7278203/ https://www.ncbi.nlm.nih.gov/pubmed/32513251 http://dx.doi.org/10.1186/s13063-020-04408-w |
| work_keys_str_mv | AT yamashitatoshinari correctiontotrastuzumabpertuzumabanderibulinmesylateversustrastuzumabpertuzumabandataxaneasafirstlineorsecondlinetreatmentforher2positivelocallyadvancedormetastaticbreastcancerstudyprotocolforarandomizedcontrollednoninferiorityphaseiiitrialinjapanjbcrgm06 AT masudanorikazu correctiontotrastuzumabpertuzumabanderibulinmesylateversustrastuzumabpertuzumabandataxaneasafirstlineorsecondlinetreatmentforher2positivelocallyadvancedormetastaticbreastcancerstudyprotocolforarandomizedcontrollednoninferiorityphaseiiitrialinjapanjbcrgm06 AT sajishigehira correctiontotrastuzumabpertuzumabanderibulinmesylateversustrastuzumabpertuzumabandataxaneasafirstlineorsecondlinetreatmentforher2positivelocallyadvancedormetastaticbreastcancerstudyprotocolforarandomizedcontrollednoninferiorityphaseiiitrialinjapanjbcrgm06 AT arakikazuhiro correctiontotrastuzumabpertuzumabanderibulinmesylateversustrastuzumabpertuzumabandataxaneasafirstlineorsecondlinetreatmentforher2positivelocallyadvancedormetastaticbreastcancerstudyprotocolforarandomizedcontrollednoninferiorityphaseiiitrialinjapanjbcrgm06 AT itoyoshinori correctiontotrastuzumabpertuzumabanderibulinmesylateversustrastuzumabpertuzumabandataxaneasafirstlineorsecondlinetreatmentforher2positivelocallyadvancedormetastaticbreastcancerstudyprotocolforarandomizedcontrollednoninferiorityphaseiiitrialinjapanjbcrgm06 AT takanotoshimi correctiontotrastuzumabpertuzumabanderibulinmesylateversustrastuzumabpertuzumabandataxaneasafirstlineorsecondlinetreatmentforher2positivelocallyadvancedormetastaticbreastcancerstudyprotocolforarandomizedcontrollednoninferiorityphaseiiitrialinjapanjbcrgm06 AT takahashimasato correctiontotrastuzumabpertuzumabanderibulinmesylateversustrastuzumabpertuzumabandataxaneasafirstlineorsecondlinetreatmentforher2positivelocallyadvancedormetastaticbreastcancerstudyprotocolforarandomizedcontrollednoninferiorityphaseiiitrialinjapanjbcrgm06 AT tsurutanijunji correctiontotrastuzumabpertuzumabanderibulinmesylateversustrastuzumabpertuzumabandataxaneasafirstlineorsecondlinetreatmentforher2positivelocallyadvancedormetastaticbreastcancerstudyprotocolforarandomizedcontrollednoninferiorityphaseiiitrialinjapanjbcrgm06 AT koizumikei correctiontotrastuzumabpertuzumabanderibulinmesylateversustrastuzumabpertuzumabandataxaneasafirstlineorsecondlinetreatmentforher2positivelocallyadvancedormetastaticbreastcancerstudyprotocolforarandomizedcontrollednoninferiorityphaseiiitrialinjapanjbcrgm06 AT kitadamasahiro correctiontotrastuzumabpertuzumabanderibulinmesylateversustrastuzumabpertuzumabandataxaneasafirstlineorsecondlinetreatmentforher2positivelocallyadvancedormetastaticbreastcancerstudyprotocolforarandomizedcontrollednoninferiorityphaseiiitrialinjapanjbcrgm06 AT kojimayasuyuki correctiontotrastuzumabpertuzumabanderibulinmesylateversustrastuzumabpertuzumabandataxaneasafirstlineorsecondlinetreatmentforher2positivelocallyadvancedormetastaticbreastcancerstudyprotocolforarandomizedcontrollednoninferiorityphaseiiitrialinjapanjbcrgm06 AT sagarayasuaki correctiontotrastuzumabpertuzumabanderibulinmesylateversustrastuzumabpertuzumabandataxaneasafirstlineorsecondlinetreatmentforher2positivelocallyadvancedormetastaticbreastcancerstudyprotocolforarandomizedcontrollednoninferiorityphaseiiitrialinjapanjbcrgm06 AT tadahiroshi correctiontotrastuzumabpertuzumabanderibulinmesylateversustrastuzumabpertuzumabandataxaneasafirstlineorsecondlinetreatmentforher2positivelocallyadvancedormetastaticbreastcancerstudyprotocolforarandomizedcontrollednoninferiorityphaseiiitrialinjapanjbcrgm06 AT iwasatsutomu correctiontotrastuzumabpertuzumabanderibulinmesylateversustrastuzumabpertuzumabandataxaneasafirstlineorsecondlinetreatmentforher2positivelocallyadvancedormetastaticbreastcancerstudyprotocolforarandomizedcontrollednoninferiorityphaseiiitrialinjapanjbcrgm06 AT kadoyatakayuki correctiontotrastuzumabpertuzumabanderibulinmesylateversustrastuzumabpertuzumabandataxaneasafirstlineorsecondlinetreatmentforher2positivelocallyadvancedormetastaticbreastcancerstudyprotocolforarandomizedcontrollednoninferiorityphaseiiitrialinjapanjbcrgm06 AT iwatanitsuguo correctiontotrastuzumabpertuzumabanderibulinmesylateversustrastuzumabpertuzumabandataxaneasafirstlineorsecondlinetreatmentforher2positivelocallyadvancedormetastaticbreastcancerstudyprotocolforarandomizedcontrollednoninferiorityphaseiiitrialinjapanjbcrgm06 AT hasegawahiroki correctiontotrastuzumabpertuzumabanderibulinmesylateversustrastuzumabpertuzumabandataxaneasafirstlineorsecondlinetreatmentforher2positivelocallyadvancedormetastaticbreastcancerstudyprotocolforarandomizedcontrollednoninferiorityphaseiiitrialinjapanjbcrgm06 AT moritasatoshi correctiontotrastuzumabpertuzumabanderibulinmesylateversustrastuzumabpertuzumabandataxaneasafirstlineorsecondlinetreatmentforher2positivelocallyadvancedormetastaticbreastcancerstudyprotocolforarandomizedcontrollednoninferiorityphaseiiitrialinjapanjbcrgm06 AT ohnoshinji correctiontotrastuzumabpertuzumabanderibulinmesylateversustrastuzumabpertuzumabandataxaneasafirstlineorsecondlinetreatmentforher2positivelocallyadvancedormetastaticbreastcancerstudyprotocolforarandomizedcontrollednoninferiorityphaseiiitrialinjapanjbcrgm06 |